SCHEMBL4356458

SCHEMBL4356458

CC[S+]([O-])c1ncc(C(=O)c2cc(F)cc(C)c2OC)c(N)n1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 7/20 0.35
CDK4 P11802 7/20 0.35
CCND1 P24385 7/20 0.35
CDK2 P24941 7/20 0.35
DHFR P00374 2/20 0.33
CSNK1D P48730 1/20 0.32
NNMT P40261 1/20 0.30
ALDH1A1 P00352 3/20 0.30
LMNA P02545 3/20 0.30
PKM P14618 1/20 0.30
SMN1; SMN2 Q16637 3/20 0.30
MAPT P10636 2/20 0.30
NPC1 O15118 1/20 0.30
TP53 P04637 1/20 0.30
RAB9A P51151 1/20 0.30
TSHR P16473 1/20 0.30
HPGD P15428 1/20 0.30
NEK2 P51955 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4354344 0.91 CDK1 (0.38) CDK1CDK4CCND1CDK2NEK2
SCHEMBL4348330 0.84 CDK1 (0.49) CDK1CDK4CCND1CDK2ALDH1A1
SCHEMBL4346982 0.83 CDK4 (0.35) CDK1CDK4CCND1CDK2CSNK1D
SCHEMBL4354997 0.82 CDK1 (0.49) CDK1CDK4CCND1CDK2LMNA
SCHEMBL4347002 0.82 CDK1 (0.36) CDK1CDK4CCND1CDK2ALDH1A1
SCHEMBL4348955 0.82 CDK1 (0.42) CDK1CDK4CCND1CDK2ALDH1A1
SCHEMBL13621474 0.80 CDK1 (0.49) CDK1CDK4CCND1CDK2LMNA
SCHEMBL4361158 0.79 SMN1; SMN2 (0.43) ALDH1A1LMNAPKMSMN1; SMN2MAPT
SCHEMBL4358951 0.79 CDK4 (0.35) CDK1CDK4CCND1CDK2CSNK1D
SCHEMBL4359313 0.78 CDK1 (0.41) CDK1CDK4CCND1CDK2CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US claimed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US claimed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US claimed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 CDK1 6/4885CDK4 1/4885CCND1 32/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 CDK1 6/4885CDK4 1/4885CCND1 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.